News | Wearables | September 09, 2015

SRI International Licenses DataSpeaks Software for Virtual Clinical Decision-Making

DataSpeaks' proprietary algorithm can generate scores suggesting dose adjustments and medication switches via patient-generated and sensor data

 

DataSpeaks, SRI International, license, SIMA, clinical decision support

September 9, 2015 — SRI International and DataSpeaks Inc. announced that SRI has licensed the Science of Individuality Measurement Algorithm (SIMA) software from DataSpeaks. SRI will integrate SIMA into the development of a secure enterprise system for clinical decision-making.

The SIMA algorithm can transform multiple streams of patient-generated and sensor data (from wearable or implantable devices) into actionable, integrated, and personalized assessments of risks (harms) and benefits for drugs in a patient's regimen. The resulting scores may be used in the future to quickly alert healthcare practitioners about potential needs for dose adjustments and medication switches.

"The unique SIMA analytic software has the capacity to synergize with other SRI platforms as a component of an integrated enterprise system designed to enhance clinical decision-making, thereby maximizing the likelihood of treatment benefit and minimizing the risk of significant side-effects related to drugs," said David Sahner, M.D., senior director, clinical translation, SRI Biosciences. "This offers the hope of major reductions in morbidity, mortality and the over $7 billion in annual healthcare costs related to the use of potentially inappropriate medications."

The in-licensing of the software was enabled by a grant from the Michigan Economic Development Corporation to establish an inter-institutional Center of Innovation focused on personalized medicine and pharmacotherapy in the elderly.

DataSpeaks' proprietary SIMA algorithm applies to multivariate time series data that are becoming ubiquitous with hospital, home, wearable, implanted, and environmental monitoring devices; apps; electronic diaries; and pill monitors. SIMA yields internally standardized scores that quantify evidence for clinically relevant interactions over time as "edges" in network graphs that are computed from data about individual patients.

Additional potential uses of SIMA include improvement of diagnostic taxonomies that may facilitate better prediction and therapy choices, identification of disease mechanisms and new drug development targets, and use in novel clinical trial designs that do not "wash out" individual patient differences.

For more information: www.dataspeaks.com, www.sri.com

Related Content

The Consumer Technology Association (CTA) is collaborating with the American College of Cardiology (ACC) and several vendors on best practices for device and app and wearable device makers to provide deeper understanding of products that manage cardiovascular health. #wearables

The Consumer Technology Association (CTA) is collaborating with the American College of Cardiology (ACC) and several vendors on best practices for device and app and wearable device makers to provide deeper understanding of products that manage cardiovascular health. 

News | Wearables | May 10, 2021
May 10, 2021 – Today, the Consumer Technology Association (CTA) announced it is collaborating with the American Colle
An example of a patch type cardiac monitor from Vital Connect. These types of inexpensive, stick-on wearable monitors have seen a tremendous increase in use over the past few years, replacing traditional Holter monitors.

An example of a patch type cardiac monitor from Vital Connect. These types of inexpensive, stick-on wearable monitors have seen a tremendous increase in use over the past few years, replacing traditional Holter monitors.

News | Wearables | May 06, 2021
May 6, 2021 — The wearable cardiac devices m...
Remote cardiac monitoring vendor RhythMedix released its next-generation RhythmStar wearable device with built-in 4G cellular connectivity. The cardiac telemetry monitor can be worn for extended remote monitoring without the need for an additional phone or communication device. 

Remote cardiac monitoring vendor RhythMedix released its next-generation RhythmStar wearable device with built-in 4G cellular connectivity. The cardiac telemetry monitor can be worn for extended remote monitoring without the need for an additional phone or communication device. 

News | Wearables | February 23, 2021
February 23, 2021 — Remote cardiac monitoring vendor RhythMedix released its next-generation RhythmStar...
Cardiac monitoring devices range from (left to right) the 12-lead ECG, Holter monitor, patch with snap fasteners, and patch with integrated electronics.

Cardiac monitoring devices range from (left to right) the 12-lead ECG, Holter monitor, patch with snap fasteners, and patch with integrated electronics.

News | Wearables | September 30, 2020
September 30, 2020 — In today’s digital age, focus on digital health and the quantified self have led to the rapid ri
The VitalPatch RTM biosensor is being used in the TELESTAR-TAVR clinical study (Deployment of Telemedicine for Symptom Tracking And Decrease Readmission Rate in TAVR Patients). It will evaluate patients who undergo a transcatheter aortic valve replacement (TAVR) and monitor them following the procedure utilizing the latest technology from VitalConnect, VistaSolution LIVE. 

The VitalPatch RTM biosensor is being used in the TELESTAR-TAVR clinical study to evaluate patients who undergo a transcatheter aortic valve replacement (TAVR) and monitor them following the procedure utilizing the latest technology from VitalConnect, VistaSolution LIVE. 

News | Wearables | September 25, 2020
September 25, 2020 — Remote and in-hospital ...
Fitbit Sense is the company’s first device compatible with an ECG app that enables users to take a spot check reading of their heart that can be analyzed for the heart rhythm irregularity atrial fibrillation (AFib).

Fitbit Sense is the company’s first device compatible with an ECG app that enables users to take a spot check reading of their heart that can be analyzed for the heart rhythm irregularity atrial fibrillation (AFib).

News | Wearables | September 24, 2020
September 24, 2020 — Fitbit received 510(k) clearance from the U.S.
A team from Purdue University developed self-powered wearable triboelectric nanogenerators with polyvinyl alcohol-based contact layers for monitoring cardiovascular health.

A team from Purdue University developed self-powered wearable triboelectric nanogenerators with polyvinyl alcohol-based contact layers for monitoring cardiovascular health.

News | Wearables | July 22, 2020
July 22, 2020 — A team from Purdue University has developed self-powered wearable triboelectric nanogenerators (TENGs
Necklace Patient Monitor Detects Abnormal Heart Rhythm. An necklace has been developed that detects abnormal heart rhythm will be showcased for the first time on EHRA Essentials 4 You, a scientific platform of the European Society of Cardiology (ESC). This wearable necklace ECG monitor provides a new and easy method for detecting an abnormal heart rhythm called atrial fibrillation and is accurate, according to a new study from the University of Eastern Finland.

This wearable necklace ECG monitor provides a new and easy method for detecting an abnormal heart rhythm called atrial fibrillation and is accurate, according to a new study from the University of Eastern Finland.

News | Wearables | May 08, 2020
May 2020 — An necklace has been developed that detects abnormal heart rhythm will be showcased for the first time on